JP2013539030A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013539030A5 JP2013539030A5 JP2013530205A JP2013530205A JP2013539030A5 JP 2013539030 A5 JP2013539030 A5 JP 2013539030A5 JP 2013530205 A JP2013530205 A JP 2013530205A JP 2013530205 A JP2013530205 A JP 2013530205A JP 2013539030 A5 JP2013539030 A5 JP 2013539030A5
- Authority
- JP
- Japan
- Prior art keywords
- value
- risk
- renal
- threshold
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 152
- 230000002485 urinary effect Effects 0.000 claims description 32
- 239000000090 biomarker Substances 0.000 claims description 28
- 230000003907 kidney function Effects 0.000 claims description 22
- 230000007423 decrease Effects 0.000 claims description 17
- 208000024891 symptom Diseases 0.000 claims description 17
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims description 16
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 15
- 102000002259 TNF-Related Apoptosis-Inducing Ligand Receptors Human genes 0.000 claims description 15
- 108010000449 TNF-Related Apoptosis-Inducing Ligand Receptors Proteins 0.000 claims description 15
- 229920002674 hyaluronan Polymers 0.000 claims description 15
- 229960003160 hyaluronic acid Drugs 0.000 claims description 15
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 claims description 14
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 claims description 14
- 208000017169 kidney disease Diseases 0.000 claims description 14
- 229940099456 transforming growth factor beta 1 Drugs 0.000 claims description 14
- 208000009304 Acute Kidney Injury Diseases 0.000 claims description 12
- 208000033626 Renal failure acute Diseases 0.000 claims description 12
- 201000011040 acute kidney failure Diseases 0.000 claims description 12
- 230000030833 cell death Effects 0.000 claims description 12
- 230000006870 function Effects 0.000 claims description 10
- 208000020832 chronic kidney disease Diseases 0.000 claims description 9
- 208000028208 end stage renal disease Diseases 0.000 claims description 9
- 201000000523 end stage renal failure Diseases 0.000 claims description 9
- 210000003734 kidney Anatomy 0.000 claims description 9
- 239000013060 biological fluid Substances 0.000 claims description 8
- 229940109239 creatinine Drugs 0.000 claims description 8
- 238000011084 recovery Methods 0.000 claims description 8
- 208000012998 acute renal failure Diseases 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 210000002700 urine Anatomy 0.000 claims description 7
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 6
- 230000004064 dysfunction Effects 0.000 claims description 6
- 210000001124 body fluid Anatomy 0.000 claims description 4
- 239000010839 body fluid Substances 0.000 claims description 4
- 230000003247 decreasing effect Effects 0.000 claims description 4
- 238000003745 diagnosis Methods 0.000 claims description 4
- ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 3
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 2
- 108010036949 Cyclosporine Proteins 0.000 claims description 2
- 206010016654 Fibrosis Diseases 0.000 claims description 2
- 206010019280 Heart failures Diseases 0.000 claims description 2
- 102000001554 Hemoglobins Human genes 0.000 claims description 2
- 108010054147 Hemoglobins Proteins 0.000 claims description 2
- 206010020772 Hypertension Diseases 0.000 claims description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 2
- 102000036675 Myoglobin Human genes 0.000 claims description 2
- 108010062374 Myoglobin Proteins 0.000 claims description 2
- 206010040047 Sepsis Diseases 0.000 claims description 2
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 claims description 2
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims description 2
- 229940126575 aminoglycoside Drugs 0.000 claims description 2
- -1 aminoglycosides Chemical compound 0.000 claims description 2
- 238000007675 cardiac surgery Methods 0.000 claims description 2
- 229960001265 ciclosporin Drugs 0.000 claims description 2
- 230000007882 cirrhosis Effects 0.000 claims description 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 239000002872 contrast media Substances 0.000 claims description 2
- 208000029078 coronary artery disease Diseases 0.000 claims description 2
- 210000004351 coronary vessel Anatomy 0.000 claims description 2
- 229930182912 cyclosporin Natural products 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 208000002296 eclampsia Diseases 0.000 claims description 2
- 229940093476 ethylene glycol Drugs 0.000 claims description 2
- 229960005102 foscarnet Drugs 0.000 claims description 2
- 230000024924 glomerular filtration Effects 0.000 claims description 2
- 229910001385 heavy metal Inorganic materials 0.000 claims description 2
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims description 2
- 229960001101 ifosfamide Drugs 0.000 claims description 2
- 239000003550 marker Substances 0.000 claims description 2
- 229960000485 methotrexate Drugs 0.000 claims description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 2
- 201000011461 pre-eclampsia Diseases 0.000 claims description 2
- 230000000750 progressive effect Effects 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 230000008085 renal dysfunction Effects 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 claims description 2
- 229960001052 streptozocin Drugs 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 229960001967 tacrolimus Drugs 0.000 claims description 2
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims description 2
- 238000007631 vascular surgery Methods 0.000 claims description 2
- 206010062237 Renal impairment Diseases 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38623010P | 2010-09-24 | 2010-09-24 | |
| US61/386,230 | 2010-09-24 | ||
| US13/235,005 US10557856B2 (en) | 2010-09-24 | 2011-09-16 | Biomarkers of renal injury |
| US13/235,005 | 2011-09-16 | ||
| PCT/US2011/052082 WO2012040073A2 (en) | 2010-09-24 | 2011-09-19 | Biomarkers of renal injury |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013539030A JP2013539030A (ja) | 2013-10-17 |
| JP2013539030A5 true JP2013539030A5 (enExample) | 2014-11-06 |
| JP5998143B2 JP5998143B2 (ja) | 2016-09-28 |
Family
ID=45871234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013530205A Active JP5998143B2 (ja) | 2010-09-24 | 2011-09-19 | 腎障害のバイオマーカー |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US10557856B2 (enExample) |
| EP (1) | EP2619577B1 (enExample) |
| JP (1) | JP5998143B2 (enExample) |
| KR (1) | KR101981745B1 (enExample) |
| CN (1) | CN103189745B (enExample) |
| AU (1) | AU2011305786B2 (enExample) |
| BR (1) | BR112013006935B1 (enExample) |
| CA (1) | CA2811658C (enExample) |
| EA (1) | EA030622B1 (enExample) |
| MX (1) | MX365029B (enExample) |
| NZ (1) | NZ608384A (enExample) |
| WO (1) | WO2012040073A2 (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102458109B (zh) | 2009-04-29 | 2015-02-11 | 阿马里纳制药公司 | 稳定的药物组合物和使用其的方法 |
| MX2011011517A (es) | 2009-04-29 | 2012-06-19 | Amarin Corp Plc | Composiciones farmaceuticas que comprenden epa y un agente cardiovascular y metodos para utilizar el mismo. |
| LT2443246T (lt) | 2009-06-15 | 2018-03-26 | Amarin Pharmaceuticals Ireland Limited | Kompozicijos ir būdai, skirti trigliceridų sumažinimui, nepakeliant ldl-c lygio subjekte, kartu taikant statino terapiją |
| US20110071176A1 (en) | 2009-09-23 | 2011-03-24 | Amarin Pharma, Inc. | Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same |
| US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| AU2011336856A1 (en) | 2010-11-29 | 2013-07-04 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| US20130282390A1 (en) * | 2012-04-20 | 2013-10-24 | International Business Machines Corporation | Combining knowledge and data driven insights for identifying risk factors in healthcare |
| WO2013184868A1 (en) * | 2012-06-06 | 2013-12-12 | The Cleveland Clinic Foundation | Prediction of acute kidney injury from a post-surgical metabolic blood panel |
| AU2013329451B2 (en) * | 2012-10-08 | 2018-08-09 | Vifor (International) Ltd. | Potassium-binding agents for treating hypertension and hyperkalemia |
| US20150265566A1 (en) | 2012-11-06 | 2015-09-24 | Amarin Pharmaceuticals Ireland Limited | Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy |
| US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
| US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
| US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
| AU2014227891A1 (en) * | 2013-03-15 | 2015-10-08 | Sera Prognostics, Inc. | Biomarkers and methods for predicting preterm birth |
| US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
| US10126305B2 (en) | 2013-06-25 | 2018-11-13 | University of Pittsburg—Of the Commonwealth System of Higher Education | Proteomic biomarkers of sepsis in elderly patients |
| GB201317621D0 (en) * | 2013-10-04 | 2013-11-20 | Randox Teoranta | Kidney disease biomarker |
| US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
| US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
| US10172818B2 (en) | 2014-06-16 | 2019-01-08 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
| US20180038873A1 (en) * | 2015-02-05 | 2018-02-08 | University Of Florida Research Foundation, Inc. | Use of nhe3 as a biomarker for radiation biodosimetry |
| EP3196791A1 (de) * | 2017-05-02 | 2017-07-26 | Siemens Healthcare GmbH | Verfahren zur unterstützung von medizinischem personal, unterstützungssystem, computerprogramm und datenträger |
| US11771113B2 (en) | 2017-05-31 | 2023-10-03 | Mars, Incorporated | Methods of diagnosing and treating chronic kidney disease |
| US11026625B2 (en) * | 2017-08-08 | 2021-06-08 | Fresenius Medical Care Holdings, Inc. | Systems and methods for treating and estimating progression of chronic kidney disease |
| WO2019144081A1 (en) | 2018-01-19 | 2019-07-25 | Mars, Incorporated | Biomarkers and classification algorithms for chronic kidney disease in cats |
| US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
| US20190317090A1 (en) * | 2018-04-12 | 2019-10-17 | Children's Hospital Medical Center | Compositions and methods for forecasting response to lupus nephritis (ln)therapy |
| US10978176B2 (en) * | 2018-06-29 | 2021-04-13 | pulseData Inc. | Machine learning systems and methods for predicting risk of renal function decline |
| US20210327589A1 (en) | 2018-07-14 | 2021-10-21 | Mars, Incorporated | Biomarkers and test models for chronic kidney disease |
| MA51766A (fr) | 2018-09-24 | 2020-12-16 | Amarin Pharmaceuticals Ie Ltd | Procédés de réduction du risque d'événements cardiovasculaires chez un sujet |
| CN109754878B (zh) * | 2018-11-30 | 2023-06-20 | 平安科技（深圳）有限公司 | 慢性肾病筛查方法、装置、设备及存储介质 |
| CN109738931B (zh) * | 2018-12-18 | 2022-06-17 | 上海瑞派益尔科技有限公司 | 一种肾小球滤过率检测设备 |
| US11350887B2 (en) | 2019-08-07 | 2022-06-07 | Fresenius Medical Care Holdings, Inc. | Systems and methods for detection of potential health issues |
| CN110596370B (zh) * | 2019-09-17 | 2023-03-24 | 广州医科大学附属第五医院 | 一种检测细菌尿路感染的酶联免疫吸附试剂盒及其应用 |
| CN114980973A (zh) | 2019-11-12 | 2022-08-30 | 阿马里纳药物爱尔兰有限公司 | 降低心房纤颤和/或心房扑动受试者心血管事件风险的方法 |
| CN110923310B (zh) * | 2019-12-24 | 2023-04-18 | 广州市妇女儿童医疗中心 | 用于指导肾病综合征cyp3a5表达型患儿使用他克莫司的多态性位点 |
| CN110904219B (zh) * | 2019-12-24 | 2023-04-18 | 广州市妇女儿童医疗中心 | Myh9及ctla4基因多态性位点在指导肾病综合征患儿使用他克莫司中的应用 |
| CA3178400A1 (en) | 2020-06-01 | 2021-12-09 | Ilias TAGKOPOULOS | System and method for chronic kidney disease of a dog |
| AU2022263358A1 (en) | 2021-04-21 | 2023-11-30 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of heart failure |
| RU2761738C1 (ru) * | 2021-06-07 | 2021-12-13 | Алина Владимировна Еремеева | Способ отбора детей с дебютом острого пиелонефрита для проведения курса противорецидивной терапии пиелонефрита |
| WO2022261513A1 (en) * | 2021-06-10 | 2022-12-15 | Kang Zhang | Methods and systems of detecting and predicting chronic kidney disease and type 2 diabetes using deep learning models |
| WO2024040225A2 (en) * | 2022-08-19 | 2024-02-22 | The Johns Hopkins University | Diagnosis and treatment of acute kidney injury |
| US20250001158A1 (en) * | 2023-06-28 | 2025-01-02 | Abiomed, Inc. | Cardiorenal syndrome (crs) therapy systems and methods |
| CN117373584B (zh) * | 2023-12-08 | 2024-03-12 | 北京大学第一医院 | 一种急性肾损伤的动态预测方法及系统 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5028535A (en) | 1989-01-10 | 1991-07-02 | Biosite Diagnostics, Inc. | Threshold ligand-receptor assay |
| US5939272A (en) | 1989-01-10 | 1999-08-17 | Biosite Diagnostics Incorporated | Non-competitive threshold ligand-receptor assays |
| US5922615A (en) | 1990-03-12 | 1999-07-13 | Biosite Diagnostics Incorporated | Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network |
| WO1992005282A1 (en) | 1990-09-14 | 1992-04-02 | Biosite Diagnostics, Inc. | Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays |
| US5955377A (en) | 1991-02-11 | 1999-09-21 | Biostar, Inc. | Methods and kits for the amplification of thin film based assays |
| ATE177841T1 (de) | 1991-04-10 | 1999-04-15 | Biosite Diagnostics Inc | ''crosstalk''- oder übersprech-inhibitoren und ihre verwendung |
| EP0579767B1 (en) | 1991-04-11 | 2000-08-23 | Biosite Diagnostics Inc. | Novel conjugates and assays for simultaneous detection of multiple ligands |
| US6143576A (en) | 1992-05-21 | 2000-11-07 | Biosite Diagnostics, Inc. | Non-porous diagnostic devices for the controlled movement of reagents |
| US5885527A (en) | 1992-05-21 | 1999-03-23 | Biosite Diagnostics, Inc. | Diagnostic devices and apparatus for the controlled movement of reagents without membrances |
| US5494829A (en) | 1992-07-31 | 1996-02-27 | Biostar, Inc. | Devices and methods for detection of an analyte based upon light interference |
| US5824799A (en) | 1993-09-24 | 1998-10-20 | Biosite Diagnostics Incorporated | Hybrid phthalocyanine derivatives and their uses |
| US6350571B1 (en) | 1996-02-01 | 2002-02-26 | Vinata B. Lokeshwar | Methods for detection and evaluation of bladder cancer |
| US6113855A (en) | 1996-11-15 | 2000-09-05 | Biosite Diagnostics, Inc. | Devices comprising multiple capillarity inducing surfaces |
| US5947124A (en) | 1997-03-11 | 1999-09-07 | Biosite Diagnostics Incorporated | Diagnostic for determining the time of a heart attack |
| US6057098A (en) | 1997-04-04 | 2000-05-02 | Biosite Diagnostics, Inc. | Polyvalent display libraries |
| CN101393165A (zh) * | 2007-09-20 | 2009-03-25 | 复旦大学附属华山医院 | 一种检测糖尿病肾病血清标本中差异表达的蛋白质谱的方法 |
| KR20100122495A (ko) * | 2008-02-29 | 2010-11-22 | 고쿠리츠 다이가쿠 호우징 나고야 다이가쿠 | 급성 신장 장해 및 예후 추정용 바이오마커 및 그 용도 |
| US20090239242A1 (en) | 2008-03-18 | 2009-09-24 | Biotrin Intellectual Properties Limited | Method for the early identification and prediction of kidney injury |
| NZ610356A (en) * | 2008-08-28 | 2015-03-27 | Astute Medical Inc | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| US9057735B2 (en) * | 2008-08-29 | 2015-06-16 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| US8501489B2 (en) * | 2008-09-26 | 2013-08-06 | University of Pittsburgh—of the Commonwealth System of Higher Education | Urinary biomarkers to predict long-term dialysis |
| CN104020284B (zh) | 2008-10-21 | 2016-08-24 | 阿斯图特医药公司 | 用于诊断和预后肾损伤和肾衰竭的方法和组合物 |
| ES2528799T3 (es) * | 2008-11-22 | 2015-02-12 | Astute Medical, Inc. | Métodos para el pronóstico de insuficiencia renal aguda |
| CN102792161B (zh) * | 2009-08-28 | 2014-11-12 | 阿斯图特医药公司 | 肾损伤和肾衰竭的诊断及预后的方法及组合物 |
| JP5763098B2 (ja) * | 2009-12-20 | 2015-08-12 | アスチュート メディカル，インコーポレイテッド | 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物 |
-
2011
- 2011-09-16 US US13/235,005 patent/US10557856B2/en active Active
- 2011-09-19 NZ NZ608384A patent/NZ608384A/en not_active IP Right Cessation
- 2011-09-19 EA EA201390439A patent/EA030622B1/ru not_active IP Right Cessation
- 2011-09-19 CA CA2811658A patent/CA2811658C/en active Active
- 2011-09-19 EP EP11827278.0A patent/EP2619577B1/en active Active
- 2011-09-19 JP JP2013530205A patent/JP5998143B2/ja active Active
- 2011-09-19 AU AU2011305786A patent/AU2011305786B2/en active Active
- 2011-09-19 MX MX2013003321A patent/MX365029B/es active IP Right Grant
- 2011-09-19 CN CN201180053315.7A patent/CN103189745B/zh active Active
- 2011-09-19 WO PCT/US2011/052082 patent/WO2012040073A2/en not_active Ceased
- 2011-09-19 KR KR1020137009232A patent/KR101981745B1/ko not_active Expired - Fee Related
- 2011-09-19 BR BR112013006935-0A patent/BR112013006935B1/pt not_active IP Right Cessation
-
2020
- 2020-01-15 US US16/743,610 patent/US11693014B2/en active Active
-
2023
- 2023-05-22 US US18/321,405 patent/US20240118289A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013539030A5 (enExample) | ||
| JP2012517594A5 (enExample) | ||
| Kusaka et al. | Serum neutrophil gelatinase-associated lipocalin as a predictor of organ recovery from delayed graft function after kidney transplantation from donors after cardiac death | |
| JP2013501920A5 (enExample) | ||
| JP2012517592A5 (enExample) | ||
| JP2013519095A5 (enExample) | ||
| JP2011520098A5 (enExample) | ||
| JP2012517593A5 (enExample) | ||
| JP2014529073A5 (enExample) | ||
| HRP20160733T1 (hr) | Postupci i pripravci za postavljanje dijagnoze i prognoze ozljede bubrega i bubrežne insuficijencije | |
| JP2013503344A5 (enExample) | ||
| JP2013531240A5 (enExample) | ||
| JP2013539861A5 (enExample) | ||
| JP2013510322A5 (enExample) | ||
| JP2015504519A5 (enExample) | ||
| JP2013519866A5 (enExample) | ||
| Delcroix et al. | NGAL usefulness in the intensive care unit three hours after cardiac surgery | |
| JP2017534874A5 (enExample) | ||
| TWI735470B (zh) | 糖尿病性腎病之判定方法、及於此種判定方法中生物標記之用途 | |
| JP6062439B2 (ja) | 早期腎障害の評価マーカーとその測定方法 | |
| JP2015513673A5 (enExample) | ||
| JP2013541005A5 (enExample) | ||
| RU2812203C1 (ru) | Способ ранней диагностики острого повреждения почек-ОПП у пациентов с острой декомпенсацией сердечной недостаточности и хронической болезнью почек | |
| Abdelhamid | Association between neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios with chronic allograft nephropathy | |
| Jaat et al. | Evaluation of laboratory profiles of hemodialysis patients in Zawia Kidney Center |